Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
2.
Artículo en Inglés | MEDLINE | ID: mdl-27895014

RESUMEN

Ceftazidime-avibactam (CAZ-AVI) is a recently approved ß-lactam-ß-lactamase inhibitor combination with the potential to treat serious infections caused by carbapenem-resistant organisms. Few patients with such infections were included in the CAZ-AVI clinical trials, and clinical experience is lacking. We present a case series of patients with infections caused by carbapenem-resistant Enterobacteriaceae (CRE) or Pseudomonas aeruginosa (CRPa) who were treated with CAZ-AVI salvage therapy on a compassionate-use basis. Physicians who had prescribed CAZ-AVI completed a case report form. We used descriptive statistics to summarize patient characteristics and treatment outcomes. We used the Wilcoxon rank sum test and Fisher's exact test to compare patients by treatment outcome. The sample included 36 patients infected with CRE and two with CRPa. The most common infections were intra-abdominal. Physicians categorized 60.5% of patients as having life-threatening infections. All but two patients received other antibiotics before CAZ-AVI, for a median of 13 days. The median duration of CAZ-AVI treatment was 16 days. Twenty-five patients (65.8%) concurrently received other antibiotics to which their pathogen was nonresistant in vitro Twenty-eight patients (73.7%, 95% confidence interval [CI], 56.9 to 86.6%) experienced clinical and/or microbiological cure. Five patients (20.8%) with documented microbiological cure died, whereas 10 patients (71.4%) with no documented microbiological cure died (P = 0.01). In three-quarters of cases, CAZ-AVI (alone or combined with other antibiotics) cured infections caused by carbapenem-resistant organisms, 95% of which had failed previous therapy. Microbiological cure was associated with improved survival. CAZ-AVI shows promising clinical results for infections for which treatment options are limited.


Asunto(s)
Antibacterianos/uso terapéutico , Compuestos de Azabiciclo/uso terapéutico , Carbapenémicos/uso terapéutico , Ceftazidima/uso terapéutico , Anciano , Antibacterianos/farmacología , Compuestos de Azabiciclo/farmacología , Carbapenémicos/farmacología , Ceftazidima/farmacología , Combinación de Medicamentos , Enterobacteriaceae/efectos de los fármacos , Enterobacteriaceae/patogenicidad , Femenino , Humanos , Klebsiella oxytoca/efectos de los fármacos , Klebsiella oxytoca/patogenicidad , Klebsiella pneumoniae/efectos de los fármacos , Klebsiella pneumoniae/patogenicidad , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Pseudomonas aeruginosa/efectos de los fármacos , Pseudomonas aeruginosa/patogenicidad , Terapia Recuperativa
3.
Diagn Microbiol Infect Dis ; 86(1): 58-60, 2016 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-27352730

RESUMEN

Molecular epidemiology allows us to know local HIV transmission and to design strategies of prevention. We studied 25 HIV newly diagnosed patients with the E138A mutation since the year 2010. Most transmission networks involved young and promiscuous men who have sex with men. Recent infection was only documented in patients grouped into the smaller clusters.


Asunto(s)
Infecciones por VIH/epidemiología , Infecciones por VIH/virología , Transcriptasa Inversa del VIH/genética , VIH/clasificación , VIH/genética , Mutación Missense , Adolescente , Adulto , Análisis por Conglomerados , Femenino , VIH/enzimología , VIH/aislamiento & purificación , Infecciones por VIH/transmisión , Humanos , Masculino , Persona de Mediana Edad , Epidemiología Molecular , España/epidemiología , Adulto Joven
4.
J Infect Chemother ; 22(8): 526-31, 2016 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-27262751

RESUMEN

OBJECTIVE: To determine the prevalence of nontuberculous mycobacteria (NTM) colonization and disease in cystic fibrosis (CF) patients. PATIENTS AND METHODS: All the CF patients followed-up from 2002 to 2012 with three acid-fast bacilli (AFB) cultures were included. The American Thoracic Society (ATS) criteria for NTM lung disease were applied. RESULTS: Forty-four of the 53 patients being followed-up were included. The mean time of follow-up was 7.0 years. A total of 18 patients (40.9%) were NTM positive. The NTN mean annual prevalence was 14.1%. The risk of Mycobacterium abscessus complex was higher in the group of 10-14 years-old (p < 0.001). Ten patients (22.7% of the entire cohort) met the ATS microbiological criteria. The mean annual prevalence of NTM disease was 10.4%. Seven patients (four with Mycobacterium simiae and three with M. abscessus complex) with multiple positive cultures, positive AFB smears and clinical worsening were treated. Three patients with M. simiae and none of those with M. abscessus were cured. CONCLUSIONS: Overall NTM prevalence of colonization and disease were high in our CF patients. Patients <15 years old had a higher risk of M. abscessus complex colonization. Multiple positive cultures or positive AFB smears were associated with disease.


Asunto(s)
Fibrosis Quística/microbiología , Infecciones por Mycobacterium no Tuberculosas/epidemiología , Infecciones por Mycobacterium no Tuberculosas/microbiología , Micobacterias no Tuberculosas/aislamiento & purificación , Adolescente , Adulto , Niño , Preescolar , Femenino , Humanos , Lactante , Recién Nacido , Pulmón/microbiología , Masculino , Persona de Mediana Edad , Prevalencia , Adulto Joven
6.
J Infect Chemother ; 22(9): 642-4, 2016 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-26964529

RESUMEN

Trueperella bernardiae is a Gram-positive coryneform bacilli which role as human pathogen is unknown because it has been usually considered a contaminant. Furthermore its identification by biochemical test was difficult. We describe a prosthetic joint infection in a women who years ago underwent a total knee replacement with superinfection and necrosis of the patellar tendon as major complications. In the sample of synovial fluid collected grew a gram-positive bacilli which was identified by matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) as T. bernardiae. The patient was treated with ciprofloxacin and currently preserves the prosthesis without signs of infection.


Asunto(s)
Antibacterianos/uso terapéutico , Arcanobacterium , Artroplastia de Reemplazo de Rodilla/efectos adversos , Ciprofloxacina/uso terapéutico , Prótesis de la Rodilla/efectos adversos , Infecciones Relacionadas con Prótesis/microbiología , Infecciones por Actinomycetales/tratamiento farmacológico , Anciano , Arcanobacterium/aislamiento & purificación , Femenino , Humanos , Ligamento Rotuliano/fisiopatología , Infecciones Relacionadas con Prótesis/diagnóstico , Infecciones Relacionadas con Prótesis/tratamiento farmacológico , Sobreinfección/diagnóstico , Sobreinfección/microbiología
7.
J Neurovirol ; 22(4): 529-32, 2016 08.
Artículo en Inglés | MEDLINE | ID: mdl-26769041

RESUMEN

We carried out a clinical and epidemiological study of adult patients with varicella-zoster virus central nervous system infection diagnosed by PCR in cerebrospinal fluid. Twenty-six patients were included. Twelve (46.2 %) patients were diagnosed with meningitis and fourteen (53.8 %) with meningoencephalitis. Twelve (46.2 %) had cranial nerves involvement (mainly the facial (VII) and vestibulocochlear (VIII) nerves), six (23.1 %) had cerebellar involvement, fourteen (53.8 %) had rash, and four (15.4 %) developed Ramsay Hunt syndrome. Three (11.5 %) patients had sequelae. Length of stay was significantly lower in patients diagnosed with meningitis and treatment with acyclovir was more frequent in patients diagnosed with meningoencephalitis. We believe routine detection of varicella-zoster virus, regardless of the presence of rash, is important because the patient may benefit from a different clinical management.


Asunto(s)
Encefalitis por Varicela Zóster/diagnóstico , Herpes Zóster Ótico/diagnóstico , Herpesvirus Humano 3/patogenicidad , Meningitis Viral/diagnóstico , Aciclovir/uso terapéutico , Adulto , Anciano , Anciano de 80 o más Años , Antivirales/uso terapéutico , Sistema Nervioso Central/patología , Sistema Nervioso Central/virología , Cerebelo/patología , Cerebelo/virología , Nervios Craneales/patología , Nervios Craneales/virología , Encefalitis por Varicela Zóster/líquido cefalorraquídeo , Encefalitis por Varicela Zóster/tratamiento farmacológico , Encefalitis por Varicela Zóster/virología , Femenino , Herpes Zóster Ótico/líquido cefalorraquídeo , Herpes Zóster Ótico/tratamiento farmacológico , Herpes Zóster Ótico/virología , Herpesvirus Humano 3/efectos de los fármacos , Herpesvirus Humano 3/fisiología , Humanos , Masculino , Meningitis Viral/líquido cefalorraquídeo , Meningitis Viral/tratamiento farmacológico , Meningitis Viral/virología , Persona de Mediana Edad , Estudios Retrospectivos , Nervio Vestibulococlear/patología , Nervio Vestibulococlear/virología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...